PRC200-SS
Source: Wikipedia, the free encyclopedia.
(Redirected from
PRC200
)Triple reuptake inhibitor investigated by the Mayo Clinic
 | |
| Identifiers | |
|---|---|
| |
JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
PRC200-SS is an experimental drug of the
Preclinical toxicology studies of PRC200-SS in cynomolgus monkeys showed dose proportional kidney toxicity,[3] precluding any further drug development
.
References
- S2CID 12635418.
- ^ "Triple Reuptake Inhibitors for the Treatment of Depression". Mayo Clinic Ventures.
- PMID 21258088.
| ||
|---|---|---|
SNRIs Tooltip Serotonin–norepinephrine reuptake inhibitors | ||
NRIs Tooltip Norepinephrine reuptake inhibitors | ||
NDRIs Tooltip Norepinephrine–dopamine reuptake inhibitors | ||
NaSSAs Tooltip Noradrenergic and specific serotonergic antidepressants | ||
SARIs Tooltip Serotonin antagonist and reuptake inhibitors | ||
SMS Tooltip Serotonin modulator and stimulators | ||
| Others |
| |
TCAs Tooltip Tricyclic antidepressants |
| |
|---|---|---|
TeCAs Tooltip Tetracyclic antidepressants | ||
| Others | ||
| |||||||
|
Miscellaneous | |
|---|---|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III